The use and effects on glycocalyx and prognosis of crystalloid or colloid for goal-directed fluid therapy in retroperitoneal tumor resection: a prospective randomized controlled clinical study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014350

Enrollment

Unknown

Registered

2018-01-07

Start date

2018-02-01

Completion date

Unknown

Last updated

2018-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retroperitoneal tumor

Interventions

crystalloid group:apply crystalloid in goal-directed ?uid therapy

colloid group:apply colloid in goal-directed fluid therapy

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: patients aged 18 to 65 years old, previously diagnosed retroperitoneal tumor, ASA I to II.

Exclusion criteria

Exclusion criteria: serious cardiopulmonary disease; other chronic diseases of the liver, renal system; coagulation disease; inflammatory disease; recent use of anti-inammatory and anti-coagulant medication; and rejection of consent.

Design outcomes

Primary

Measure	Time frame
Syndecan-1;HA;HS;	—

Secondary

Measure	Time frame
IL-6;TNF-a;CRP;	—

Countries

China

Contacts

Public ContactZhifeng Gao

Peking University International Hospital

gao79@126.com+86 15801249466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026